New therapeutic strategy against the Ebola virus

Carmen Gil

  • PROJECT LEADER

    Carmen Gil

  • HOST ORGANIZATION,
    COUNTRY

    Centro de Investigaciones Biológicas. Consejo Superior de Investigaciones Científicas (CIB-CSIC), Spain

  • DESCRIPTION

    The Ebola virus disease is a very serious disease with high human mortality rates: outbreaks can reach a mortality rate of 50 %. The vaccines developed so far have not yet been evaluated globally and complementary treatment with therapeutic antivirals is necessary.

    The aim of the project is to develop antivirals capable of blocking the cellular receptor of the virus to avoid invasion by the virus. Once these compounds are developed, efficacy will be tested in animal models for the subsequent design of a clinical transfer strategy.

  • CONSORTIUM
    (PRINCIPAL INVESTIGATOR,
    ORGANIZATION, COUNTRY)

    • Rafael Delgado, Instituto de Investigación Biomédica Hospital 12 de Octubre (Imas12), Spain

    • Covadonga Alonso, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Spain

    • Cesar Muñoz-Fontela, Bernhard Nocht Institute for Tropical Medicine, Germany

  • PROJECT TITLE

    Locking cells against Ebola virus

  • BUDGET

    €995,068